1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. Hepatology. 2015; 62(3): 932-54.
2. Wang X., Gao F., Yuan G., Shi K., Huang Y., Chen Y., et al. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. J. Viral. Hepat. 2016; 23(12): 971-6.
3. Pafundi P.C., Parrella A., Iossa D., Molaro R., Battimelli C., Falco E., et al. Viability of pegIFNα-RBV for CHC in the direct acting antiviral era: a practical algorithm between efficacy and cost containment. J. Chemother. 2016; (8): 1-8.
4. Enaleeva D.Sh., Fazylov V.Kh., Sozinov A.S. Khronicheskie virusnye gepatity V, S i D: rukovodstvo dlya vrachei. M.: MEDpress-inform; 2011.
5. Yushchuk N.D., Klimova E.A., Znoiko O.O., Karetkina S.L., Maksimov I.V., Maev I.V. Virusnye gepatity. Klinika, diagnostika, lechenie. M.: GEOTAR-MED, 2014.